Advertisement
AMGN vs GILD
Which Stock Would AI Choose? Amgen (AMGN) vs. Gilead Sciences (GILD) Stock Comparison
Key Takeaways
- Both are large-cap biopharmaceutical leaders trading near 52-week highs, but AMGN has posted stronger trailing 12-month and year-to-date gains than GILD.
- Gilead recently delivered a third-quarter earnings and revenue beat and raised its full-year sales guidance, supported by 18% growth in its core HIV (human immunodeficiency virus) franchise.
- Amgen's momentum has been driven by positive late-stage clinical data and improving earnings, yet its valuation now sits above the consensus analyst price target.
- Analyst sentiment diverges sharply: GILD carries a consensus "Buy" with rising price targets, while AMGN carries a consensus "Hold" with an average target below the current share price.
- Tickeron AI Verdict: Tickeron's AI currently favors GILD (Gilead Sciences), reflecting its earnings beat, raised guidance, and comparatively stronger analyst positioning.
- For deeper context on each name, explore AMGN Major News and AMGN Today's Price Move, along with GILD Major News and GILD Today's Price Move.
- For automated, AI-driven market ideas across thousands of tickers, explore the curated Trending AI Robots.
Introduction
Amgen Inc. and Gilead Sciences, Inc. are two of the largest and most closely watched names in the biotechnology and pharmaceutical space, and both have enjoyed a period of notable strength in recent market activity. Because the two companies overlap in oncology, inflammation, and their reliance on blockbuster franchises, investors frequently weigh them as alternative ways to gain exposure to large-cap healthcare. This stock comparison is most relevant to traders and investors evaluating relative performance, market positioning, and momentum between two industry giants at a time when both are trading near multi-year or all-time highs.
AMGN Overview and Recent Performance
Amgen is a Thousand Oaks, California-based biotechnology company with a diversified portfolio spanning oncology, cardiovascular disease, inflammation, and rare diseases, anchored by well-known products such as Enbrel, Prolia, Repatha, and Tepezza. In recent weeks, the stock has been a standout performer, supported by a series of positive late-stage clinical readouts, including Phase 3 data for IMDELLTRA in small cell lung cancer, Tezspire in eosinophilic esophagitis, and dazodalibep in Sjögren's disease. These catalysts, combined with improving quarterly earnings, have lifted sentiment and pushed the share price toward its 52-week high. However, the strength has also stretched the valuation, with the consensus analyst rating at "Hold" and an average 12-month price target that sits below the current trading level, signaling that some of the upside may already be reflected in the price.
GILD Overview and Recent Performance
Gilead Sciences, headquartered in Foster City, California, is a biopharmaceutical company best known for its leadership in HIV treatment and prevention, alongside growing franchises in oncology, liver disease, and inflammation. Recent market activity has been constructive for the stock, which has risen toward the top of its 52-week range. Gilead's most recent quarterly report exceeded expectations, with adjusted earnings per share and revenue both beating consensus estimates, while management raised its full-year sales guidance. The company's HIV business grew 18% year over year, driven by demand for Biktarvy and its prevention portfolio, and it reported record U.S. HIV treatment market share. Offsetting these positives are large acquired in-process research and development (IPR&D) charges tied to recent transactions, which widened the company's near-term loss outlook and highlight the costs of its pipeline-building strategy.
Trending AI Robots
Tickeron maintains hundreds of AI trading bots that collectively trade thousands of different tickers, each configured with its own trading style, strategy, timeframe, and performance profile. Because market conditions change, not every bot is equally suited to the current environment at any given moment. The Trending AI Robots page curates only the strongest, most relevant bots for present conditions, presenting their performance statistics, trading styles, and the sets of tickers they monitor so that traders can evaluate them side by side. Whether you are a short-term trader or a longer-horizon investor, exploring these curated strategies can offer a data-driven way to complement your own research on names like AMGN and GILD.
Head-to-Head Comparison
The two companies differ meaningfully in growth drivers and risk profiles. Amgen's recent outperformance leans heavily on clinical catalysts and its push into obesity and oncology, while Gilead's strength is anchored in a dominant, cash-generative HIV franchise now expanding into prevention. From a momentum standpoint, both are near 52-week highs, but Amgen's trailing returns are stronger. Valuation and analyst positioning tell a different story: Gilead holds a consensus "Buy" with price targets recently raised above its market price, whereas Amgen carries a "Hold" and a consensus target below its current level, reflecting caution about how much of its pipeline optimism is already priced in. Risk factors also diverge—Amgen faces questions about manufacturing scale for its newer programs and a high debt load, while Gilead confronts a projected Medicare pricing headwind on Biktarvy beginning in 2028. In short, Amgen offers stronger recent momentum but a more stretched valuation, while Gilead offers steadier franchise cash flow and more supportive analyst sentiment.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings catalysts, and relative positioning, Tickeron's AI would currently lean toward Gilead Sciences (GILD). The combination of a top-and-bottom-line earnings beat, raised full-year sales guidance, robust HIV franchise growth, and a consensus "Buy" rating with rising price targets suggests a more balanced risk-reward profile than Amgen's stronger momentum paired with a valuation already above its average analyst target. This probabilistic assessment reflects current data and market conditions rather than a definitive prediction, and relative positioning between the two names could shift as new earnings, clinical, and policy developments emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Buy and GILD is a Buy.
AMGN in upward trend: 10-day moving average crossed above 50-day moving average on October 16, 2026
The 10-day moving average for AMGN crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on AMGN as a result. In 43 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
AMGN moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in 194 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 151 of 272 cases where AMGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.
Bearish Trend Analysis
The 10-day RSI Indicator for AMGN moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator moved out of overbought territory. In 27 of the 46 cases, the stock moved lower in the following days. This puts the odds of a move lower at 59%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 67 cases where AMGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 48%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
AMGN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 9 (best 1 - 100 worst), indicating outstanding price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.297) is normal, around the industry mean (-1.421). P/E Ratio (28.386) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (2.524) is also within normal values, averaging (5.738). Dividend Yield (0.022) settles around the average of (0.038) among similar stocks. P/S Ratio (5.371) is also within normal values, averaging (4.033).
GILD's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for GILD turned positive on October 14, 2026. Looking at past instances where GILD's MACD turned positive, the stock continued to rise in 40 of 54 cases over the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on GILD as a result. In 59 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
Following a +2.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where GILD advanced for three days, in 215 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 167 of 276 cases where GILD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
Bearish Trend Analysis
The 10-day RSI Indicator for GILD moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 17 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 44%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 24 of 63 cases where GILD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 38%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GILD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
GILD broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 8 (best 1 - 100 worst), indicating outstanding price growth. GILD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.495) is normal, around the industry mean (-1.421). GILD's P/E Ratio (-63.943) is considerably lower than the industry average of (21.700). Projected Growth (PEG Ratio) (2.263) is also within normal values, averaging (5.738). Dividend Yield (0.020) settles around the average of (0.038) among similar stocks. P/S Ratio (6.053) is also within normal values, averaging (4.033).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
AMGN | GILD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 40 | 26 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | 32 Undervalued | |
PROFIT vs RISK RATING 1..100 | 3 | 5 | |
SMR RATING 1..100 | 15 | 96 | |
PRICE GROWTH RATING 1..100 | 9 | 8 | |
P/E GROWTH RATING 1..100 | 28 | 100 | |
SEASONALITY SCORE 1..100 | 26 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GILD's Valuation (32) in the Biotechnology industry is somewhat better than the same rating for AMGN (79). This means that GILD’s stock grew somewhat faster than AMGN’s over the last 12 months.
AMGN's Profit vs Risk Rating (3) in the Biotechnology industry is in the same range as GILD (5). This means that AMGN’s stock grew similarly to GILD’s over the last 12 months.
AMGN's SMR Rating (15) in the Biotechnology industry is significantly better than the same rating for GILD (96). This means that AMGN’s stock grew significantly faster than GILD’s over the last 12 months.
GILD's Price Growth Rating (8) in the Biotechnology industry is in the same range as AMGN (9). This means that GILD’s stock grew similarly to AMGN’s over the last 12 months.
AMGN's P/E Growth Rating (28) in the Biotechnology industry is significantly better than the same rating for GILD (100). This means that AMGN’s stock grew significantly faster than GILD’s over the last 12 months.
| AMGN | GILD | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 59% | 2 days ago 44% |
| Stochastic ODDS (%) | 2 days ago 48% | 2 days ago 38% |
| Momentum ODDS (%) | 2 days ago 59% | 2 days ago 71% |
| MACD ODDS (%) | N/A | 2 days ago 74% |
| TrendWeek ODDS (%) | 2 days ago 63% | 2 days ago 63% |
| TrendMonth ODDS (%) | 2 days ago 60% | 2 days ago 64% |
| Advances ODDS (%) | 3 days ago 62% | 2 days ago 64% |
| Declines ODDS (%) | 9 days ago 47% | 6 days ago 47% |
| BollingerBands ODDS (%) | 2 days ago 51% | 2 days ago 43% |
| Aroon ODDS (%) | 2 days ago 56% | 2 days ago 61% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 4 FA rating(s) are green while GILD’s FA Score has 3 green FA rating(s).
- AMGN’s FA Score: 4 green, 1 red.
- GILD’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 5 TA indicator(s) are bullish while GILD’s TA Score has 4 bullish TA indicator(s).
- AMGN’s TA Score: 5 bullish, 4 bearish.
- GILD’s TA Score: 4 bullish, 4 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +0.86% price change this week, while GILD (@Pharmaceuticals: Major) price change was +2.03% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.33%. For the same industry, the average monthly price growth was +2.53%, and the average quarterly price growth was +7.15%.
Reported Earning Dates
AMGN is expected to report earnings on Feb 09, 2027.
GILD is expected to report earnings on Feb 04, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (-1.33% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
GILD and
Correlation & Price change
A.I.dvisor indicates that over the last year, GILD has been loosely correlated with AMGN. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if GILD jumps, then AMGN could also see price increases.
| Ticker / NAME | Correlation To GILD | 1D Price Change % | ||
|---|---|---|---|---|
| GILD | 100% | +0.92% | ||
| AMGN - GILD | 56% Loosely correlated | N/A | ||
| SNY - GILD | 43% Loosely correlated | +0.23% | ||
| AZN - GILD | 39% Loosely correlated | -1.39% | ||
| JNJ - GILD | 39% Loosely correlated | -0.47% | ||
| ABBV - GILD | 39% Loosely correlated | +0.20% | ||
More | ||||